Ep.4 - Peptide Pulse and AMA

About this video

This long ask-me-anything style episode ranges across Seeds’ peptide framework. He discusses the evolution of GLP-1 medicines, arguing newer generations improve tolerability and that care should focus on pancreatic beta cell resilience, mitochondrial oxidative stress and epigenetic regulation, while criticizing one-size-fits-all talk about low dosing and noting access and cost tensions between branded products, insurers and compounding pharmacies — a topic he says needs careful distinction. He then turns to growth hormone secretagogues, mitochondrial quality control including fission, fusion and mitofusin proteins and HIF signaling in muscle and cancer, and argues peptides should be understood as context-dependent modulators, not simple on-switches.

Key takeaways

• Seeds frames GLP-1 care around beta cell resilience and metabolic environment, not weight alone
• Dosing debates cannot be settled generically; Seeds argues individual context and purpose decide
• Mitochondrial fission and fusion are presented as quality-control decisions with muscle and disease implications
• Peptides are described as modulators whose effect depends on the cellular environment
• Cost, insurance and compounding access are treated as real constraints shaping peptide medicine

Episode details: published June 30, 2026 · 155 views · 59:50 long. Summary written by Self Growth Videos from the episode itself. The peptide and cellular-medicine concepts described are Dr. William Seeds’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: the SSRP Institute sells clinician certification in peptide therapy.

← Previous: Ep.65 - Live Episode From Peptide World Congress 2026 · Next: Ep.7 - Peptides for Cellular Healing The Next Big Thing in Medicine →

All Dr. William Seeds videos · Dr. William Seeds profile · SSRP Institute (official site)